Table 1.
Magnetic Resonance Imaging Parameters.
Table 2.
Distribution of benign and malignant lesions.
Table 3.
Scan duration of one whole-body CT, PET/CT examination as well as for ultra-fast protocol for whole-body PET/MR imaging.
Fig 1.
Estimated Effective Dose (ED) of PET/CT, CT, and PET/MRI.
Fig 2.
A 46-year-old patient with recurrent cervical cancer.
Tumor lesion originating from right ovary with contact to the small bowel is hardly detectable in CT (A). The identical lesion shows a slightly higher lesion contrast in the post-contrast VIBE sequence in MRI (C). In fused PET/CT (B) and PET/MR (D) images the lesion can be equally clearly identified as a metastasis.
Fig 3.
Images of a 58-year-old patient with recurrence of ovarian cancer.
CT image (A) shows a peritoneal mass next to the liver with pathological FDG metabolism in fused PET/CT images (B). The same lesion is visible in post-contrast media VIBE sequence in MRI (C) and in PET/MRI (D). No FDG metabolism can be seen in a benign liver cyst in PET/CT or PET/MRI (A-D).